Abstract P3-11-03: A randomized, phase 2 trial of preoperative MM-121 with paclitaxel in triple negative (TN) and hormone receptor (HR) positive, HER2-negative breast cancer

Mapping Intimacies ◽

10.1158/1538-7445.sabcs14-p3-11-03 ◽

2015 ◽

Cited By ~ 4

Author(s):

Frankie A Holmes ◽

Kristi J McIntyre ◽

Ian E Krop ◽

Cynthia R Osborne ◽

John W Smith II ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Triple Negative ◽

Phase 2 ◽

Phase 2 Trial ◽

Randomized Phase 2

Download Full-text

Abstract PD1-06: Trilaciclib improves overall survival when given with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: Final analysis of a randomized phase 2 trial

10.1158/1538-7445.sabcs20-pd1-06 ◽

2021 ◽

Author(s):

Joyce O'Shaughnessy ◽

Gail S Wright ◽

Anu R Thummala ◽

Michael A Danso ◽

Lazar Popovic ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Final Analysis ◽

Phase 2 ◽

Phase 2 Trial ◽

Randomized Phase 2

Download Full-text

Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial

Oncotarget ◽

10.18632/oncotarget.10607 ◽

2016 ◽

Vol 7 (37) ◽

pp. 60647-60656 ◽

Cited By ~ 26

Author(s):

Pin Zhang ◽

Yi Yin ◽

Hongnan Mo ◽

Bailin Zhang ◽

Xiang Wang ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Locally Advanced ◽

Pathologic Complete Response ◽

Complete Response ◽

Phase 2 ◽

Relapse Free Survival ◽

Free Survival ◽

Phase 2 Trial ◽

Randomized Phase 2

Download Full-text

Abstract 2964: On-treatment changes in circulating tumor DNA (ctDNA) level as an early predictor of clinical outcome in the LOTUS randomized phase 2 trial of 1st-line ipatasertib (IPAT) + paclitaxel (PAC) for metastatic triple-negative breast cancer (mTNBC)

10.1158/1538-7445.am2018-2964 ◽

2018 ◽

Author(s):

Matthew J. Wongchenko ◽

Doron Lipson ◽

Travis Clark ◽

Mark Kennedy ◽

Mandy Greene ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Outcome ◽

Triple Negative ◽

Circulating Tumor Dna ◽

Phase 2 ◽

Phase 2 Trial ◽

Treatment Changes ◽

Tumor Dna ◽

Early Predictor ◽

Randomized Phase 2

Download Full-text

Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer

Case Medical Research ◽

10.31525/ct1-nct04083963 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase 2 ◽

Phase 2 Trial

Download Full-text

Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor‐positive, HER2 ‐negative metastatic breast cancer

International Journal of Cancer ◽

10.1002/ijc.33613 ◽

2021 ◽

Author(s):

Hyehyun Jeong ◽

Jae Ho Jeong ◽

Jeong Eun Kim ◽

Jin‐Hee Ahn ◽

Kyung Hae Jung ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Protective Effects ◽

Phase 2 ◽

Hormone Receptor Positive ◽

Randomized Phase 2

Download Full-text

Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up

Breast Cancer Research and Treatment ◽

10.1007/s10549-021-06401-6 ◽

2021 ◽

Author(s):

Fangchao Zheng ◽

Feng Du ◽

Wenmiao Wang ◽

Yongsheng Wang ◽

Ming Li ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase 2 ◽

Phase 2 Trial

Download Full-text

Abstract 1767: Analysis of biomarkers and anthracycline benefit for hormone receptor-negative breast cancer: results from a randomized phase 2 neoadjuvant study (KBOG 1101 Study)

10.1158/1538-7445.am2017-1767 ◽

2017 ◽

Author(s):

Takashi Ishikawa ◽

Kazutaka Narui ◽

Mari S. Oba ◽

Akimitsu Yamada ◽

Kumiko Kida ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Phase 2 ◽

Randomized Phase 2

Download Full-text

Abstract P6-16-03: Phase 2 trial of everolimus and/or trastuzumab in hormone refractory, hormone receptor (HR)-positive, HER2-normal metastatic breast cancer (MBC)

10.1158/1538-7445.sabcs16-p6-16-03 ◽

2017 ◽

Author(s):

E Paplomata ◽

K Gogineni ◽

J Meisel ◽

C Santa-Maria ◽

L Yuan ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Phase 2 ◽

Phase 2 Trial ◽

Hormone Refractory

Download Full-text

Abstract P4-14-08: Apatinib combined with docetaxel and platinum as neoadjuvant treatment for triple-negative/HER2-positive breast cancer: A randomized, open-label, multicenter, phase 2 trial

10.1158/1538-7445.sabcs19-p4-14-08 ◽

2020 ◽

Author(s):

Yunjiang Liu ◽

Shuo Zhang

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Neoadjuvant Treatment ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Her2 Positive Breast Cancer ◽

Phase 2 Trial ◽

Multicenter Phase ◽

Positive Breast Cancer

Download Full-text

Trasutuzumab versus observation for high-risk, non-metastatic, HER2 non-amplified breast cancer with Circulating Tumor Cells (EORTC 90091-10093 Treat CTC): A European, multicenter, randomized phase 2 trial

European Journal of Cancer ◽

10.1016/s0959-8049(18)30263-6 ◽

2018 ◽

Vol 92 ◽

pp. S7

Author(s):

M. Ignatiadis ◽

S. Litiere ◽

F. Rothe ◽

S. Riethdorf ◽

C. Proudhon ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Phase 2 ◽

Phase 2 Trial ◽

Randomized Phase 2

Download Full-text